Abstract
Multiple myeloma is a neoplastic plasma-cell dyscrasia that will cause more than 11,000 deaths in 2005 in the United States alone.1 The usefulness of the many therapies for multiple myeloma is limited, and virtually all patients eventually die from the disease. When thalidomide was shown to be effective against relapsed myeloma in 1999,2 more than 30 years had elapsed since a clinical response to any single agent had been reported in at least 25 percent of treated patients.35 By the early 2000s, it had become clear that another two agents — lenolidomide6 and bortezomib7 — had activity against malignant . . .

This publication has 11 references indexed in Scilit: